Proliferation in adrenocortical tumors: Correlation with clinical outcome and p53 status
Proliferation in adrenocortical tumors: Correlation with clinical outcome and p53 status
复制标题
DOI：
10.1007/bf02739705
复制
发表时间：
1997-03-01
影响因子：
4.4
通讯作者：
Haak, HR
中科院分区：
文献类型：
--
作者：
McNicol, AM;Struthers, AJ;Haak, HR
有丝分裂活性与肾上腺皮质肿瘤的恶性行为有关，有丝分裂指数高的肿瘤预后可能较差。通过使用抗体MIB-1对一系列14例肾上腺皮质腺瘤和40例癌的Ki-67指数进行量化和比较，进一步研究了这一点。这一水平与癌症的存活率和无病存活率以及免疫组织化学检测到的P53异常表达的证据相关。然而，许多癌症的增殖水平较低，这可能反映了细胞分裂和凋亡调节的不同异常。因此，还检测了细胞凋亡抑制因子bcl2蛋白的表达。Ki-67指数在癌组织中显著高于腺瘤组织，但在4%以下有重叠。MIB-1指数不同的癌患者的生存率无显著差异
There appears to be a relationship between mitotic activity and malignant behavior in adrenocortical tumors, and carcinomas with a high mitotic index may have a poorer prognosis. This has been investigated further by quantifying and comparing the Ki-67 index using antibody MIB-1 in a series of 14 adrenocortical adenomas and 40 carcinomas. The levels have been correlated with survival and disease-free survival in carcinomas and with evidence of abnormal p53 expression as detected by immunohistochemistry. Nevertheless, many carcinomas have a low level of proliferation that may reflect varying abnormalities within the regulation of both cell division and apoptosis. Expression of bcl-2 protein, an inhibitor of apoptosis has therefore also been examined. The Ki-67 index in carcinomas was significantly higher than in adenomas, but below 4% there was overlap. There was no significant difference in survival between carcinomas with MIB-1 index